Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.37M Buy
175,717
+8,513
+5% +$119K 0.01% 832
2025
Q4
$2.08M Buy
167,204
+5,249
+3% +$56.6K 0.01% 838
2025
Q3
$1.6M Buy
161,955
+1,345
+0.8% +$13.1K 0.01% 856
2025
Q2
$1.44M Buy
160,610
+76,566
+91% +$647K 0.01% 807
2025
Q1
$729K Buy
84,044
+28,125
+50% +$295K 0.01% 955
2024
Q4
$687K Buy
55,919
+9,353
+20% +$115K 0.01% 925
2024
Q3
$541K Buy
46,566
+23,689
+104% +$273K 0.01% 833
2024
Q2
$243K Buy
+22,877
New +$253K 0.01% 785

Other funds holding VTRS

&Partners's VTRS Position: Q1 2026 in Review

&Partners increased its Viatris (VTRS) stake by 5.1% in Q1 2026, buying an estimated $119K and bringing the position to 175,717 shares worth $2.37M. The position accounts for 0.01% of the portfolio, ranked #832.

&Partners first reported a position in VTRS in Q2 2024 and has held it in 8 quarters since. 1,019 funds tracked by Wall St. Rank hold VTRS as of Q1 2026.

  • &Partners held 175,717 shares of Viatris worth $2.37M as of Q1 2026.
  • &Partners bought 8,513 Viatris shares in Q1 2026, an estimated $119K.
  • Viatris made up 0.01% of &Partners's portfolio in Q1 2026, its #832 holding.
  • &Partners first reported a position in Viatris in Q2 2024 and has held it in 8 quarters since.
  • 1,019 funds tracked by Wall St. Rank held Viatris as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.